Phenytoin Dose Adjustment for Subtherapeutic Level
Increase the phenytoin dose to 400 mg daily (either 200 mg twice daily or 100 mg four times daily) and recheck the serum level in 7-10 days, as phenytoin exhibits nonlinear (Michaelis-Menten) pharmacokinetics where small dose increases can produce disproportionately large increases in serum concentration. 1
Understanding the Current Situation
Your patient is taking 300 mg daily (100 mg TID) with a critically subtherapeutic level of 0.6 µg/mL, far below the therapeutic range of 10-20 µg/mL. 2, 1 This extremely low level indicates either:
- Severe non-compliance (most likely)
- Malabsorption
- Drug interactions increasing metabolism
- Inadequate dosing for this patient's metabolic capacity
Dose Adjustment Strategy
Initial Dose Increase
- Increase to 400 mg daily as the first step, which represents a 33% increase from the current 300 mg dose 1
- This can be given as 100 mg four times daily or 200 mg twice daily 1
- The FDA-approved adult dosage range extends up to 600 mg daily (two 100-mg capsules three times daily) if necessary 1
Critical Pharmacokinetic Consideration
Phenytoin follows nonlinear (Michaelis-Menten) kinetics, meaning the relationship between dose and serum concentration is NOT proportional. 3, 4, 5 At low serum concentrations like 0.6 µg/mL, your patient is operating well below enzyme saturation, so dose increases will initially produce relatively linear increases in concentration. However, as levels approach 10-15 µg/mL, small dose increments can cause disproportionately large concentration increases. 6, 7
Timing of Follow-up Level
- Recheck the serum phenytoin level 7-10 days after the dose change to allow achievement of steady-state 2, 1
- Steady-state concentrations require 3-7 days (typically 7-8 days) of consistent daily dosing 2
- Do NOT make further dose adjustments before 7 days, as premature changes will lead to unpredictable levels 1
Subsequent Dose Titration
If the level remains subtherapeutic after 7-10 days on 400 mg daily:
- Increase by 100 mg increments (to 500 mg, then 600 mg if needed) 1
- Wait another 7-10 days between each adjustment 1
- Once levels reach 5-10 µg/mL, switch to smaller 25-50 mg increments to avoid overshooting into toxicity, as the dose-concentration relationship becomes steeper in the therapeutic range 7
Alternative Dosing Equations
For more precise dose prediction using the single measured level, you can apply population pharmacokinetic equations:
Using the power equation: D₂ = D₁ × C₁⁻ⁿ × C₂ⁿ, where n = 0.312 3
- D₁ = 300 mg (current dose)
- C₁ = 0.6 µg/mL (current level)
- C₂ = 15 µg/mL (target mid-therapeutic level)
- This predicts approximately 450-500 mg daily would be needed
Using the clearance-based equation: Dₙ = D₀ × C₀⁻⁽ᵇ⁺¹⁾ × Cₐ⁽ᵇ⁺¹⁾, where b = -0.6786 4
- This similarly predicts 450-500 mg daily for a target of 15 µg/mL
However, these equations are most accurate when the initial level is closer to the therapeutic range. 5
Critical Pitfalls to Avoid
- Never assume linear kinetics: A common error is calculating that if 300 mg produces 0.6 µg/mL, then 5000 mg would be needed for 10 µg/mL—this is incorrect due to nonlinear pharmacokinetics 3, 4
- Avoid aggressive dose escalation: Once levels exceed 10 µg/mL, increase doses by only 25-50 mg at a time, as the steep dose-concentration curve in the therapeutic range makes toxicity likely with 100 mg increments 7
- Don't recheck levels too early: Levels drawn before 7 days will not reflect steady-state and will lead to inappropriate dose adjustments 1
- Consider compliance first: A level of 0.6 µg/mL strongly suggests non-adherence rather than true pharmacokinetic issues—address this before assuming the patient needs extremely high doses 1
Monitoring for Toxicity
Once therapeutic levels are approached, monitor for dose-related adverse effects including:
- Ataxia, nystagmus, tremor, somnolence 8, 9
- These typically occur at levels >20 µg/mL but can occur at lower levels in some patients 2
Special Populations
- Renal insufficiency (CrCl <50 mL/min): More frequent monitoring is needed due to altered protein binding affecting free drug concentrations 2
- Hypoalbuminemia: Consider measuring free phenytoin levels, as the Sheiner-Tozer equation for calculating free levels has only moderate accuracy in critically ill patients 10, 11